HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a
Authors:
- Christian M. LangeCLChristian M. Lange
- Simone SusserSSSimone Susser
- Eva HerrmannEHEva Herrmann
- Ursula KareyUKUrsula Karey
- Tara L. KiefferTKTara L. Kieffer
- Ann D. KwongAKAnn D. Kwong
- Janke SchinkelJSJanke Schinkel
- Henk W. ReesinkHRHenk W. Reesink
- Stefan ZeuzemSZStefan Zeuzem
- Christoph SarrazinCSChristoph Sarrazin
- 5 August 2011
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (11) , 1362-1368
Abstract
Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.Keywords
This publication has 23 references indexed in Scilit:
- Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapyAlimentary Pharmacology & Therapeutics, 2010
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus InfectionGastroenterology, 2010
- Dynamic Hepatitis C Virus Genotypic and Phenotypic Changes in Patients Treated With the Protease Inhibitor TelaprevirGastroenterology, 2007
- Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized StudyGastroenterology, 2006
- Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3*1, *2Journal of Hepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virusNature, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998